
Novartis’ serelaxin was once thought to be the major hope for its cardiovascular pipeline – analysts projected it to become …

The prospects of Novartis’ latest heart drug being approved in the US anytime soon appear to have been scuppered by …
Novartis’ new treatment for heart failure has been granted Breakthrough Therapy designation status by the FDA. RLX030 (serelaxin) is for …
Jager-van Dijk is new Arletta Pharma Solutions CEOÂ
Tridem begins phase Ib trial of Parkinson’s disease vaccine
Trio become latest Symbiosis commercial additions
UK immunoglobulin supply faces growing pressure, report warns

